Paris, France, March 10, 2023, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate and present LUMEVOQ® data at the following upcoming medical conferences taking place in the first half of 2023:

 

North American Neuro Ophthalmology Society (NANOS) 49th Annual Meeting

March 11 – 16, 2023 – Orlando, USA

 

Presentation: “Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs”

  • Type: Poster
  • Presenter: Catherine Vignal, MD, Quinze-Vingts National Eye Hospital, Paris, France
  • Time: Tuesday, March 14th, 2023 from 6:00 – 8:30 pm ET
  • Location: National Ballroom

 

Presentation: “Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4 LHON patients: the RESTORE study”

  • Type: Poster
  • Presenter: Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, United Kingdom
  • Time: Tuesday, March 14th, 2023 from 6:00 – 8:30 pm ET
  • Location: National Ballroom

 

Presentation: “Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in m.11778G>A MT-ND4 Leber hereditary optic neuropathy patients”

  • Type: Poster
  • Presenter: Mark L. Moster, MD, Wills Eye Hospital and Thomas Jefferson University, Philadelphia, USA
  • Time: Tuesday, March 14th, 2023 from 6:00 – 8:30 pm ET
  • Location: National Ballroom

 

Presentation: “Bilateral improvement after unilateral AAV2 gene therapy for LHON: update and bilateral ocular post-mortem analyses”

  • Type: Oral
  • Presenter: Alfredo A. Sadun, MD, PhD, Doheny Eye Institute, UCLA School of Medicine, Los Angeles, USA
  • Time: Tuesday, March 14th, 2023 at 10:15 am ET
  • Location: International Ballroom I-II

 

The American Academy of Neurology (AAN) Annual Meeting

April 22 – 27, 2023 – Boston, USA

 

Presentation: “Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in m.11778G>A MT-ND4 Leber hereditary optic neuropathy patients”

  • Type: Oral
  • Presenter: Nancy J. Newman, MD, Emory University School of Medicine, Atlanta, USA, Principal Investigator of REFLECT
  • Time: Monday, April 24th, 2023 at 11:51 am ET

 

Presentation: “Long-term follow-up of m.11778G>A MT-ND4-LHON patients treated with lenadogene nolparvovec ocular gene therapy: the RESTORE study”

  • Type: Oral
  • Presenter: Valérie Biousse, MD, Emory University School of Medicine, Atlanta, USA
  • Time: Monday, April 24th, 2023 at 12:03 pm ET

 

The Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting

April 23 – 27, 2023 – New Orleans, USA

 

Presentation: “Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs”

  • Type: Oral
  • Presenter: Chiara La Morgia, MD, PhD, IRCCS Institute of Neurological Science, Bologna, Italy
  • Time: Monday, April 24th, 2023 at 4:15 pm CDT
  • Location: Room 344

 

Presentation: “Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4-LHON patients: the RESTORE study”

  • Type: Oral
  • Presenter: Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, United Kingdom
  • Time: Monday, April 24th, 2023 at 4:00 pm CDT
  • Location: Room 344

 

Presentation: “Histopathological and molecular characterization in ocular post-mortem analyses following AAV2 gene therapy for LHON”

  • Type: Poster
  • Presenter: Alfredo A. Sadun, MD, PhD, Doheny Eye Institute, UCLA School of Medicine, Los Angeles, USA
  • Time: Wednesday, April 26th, 2023 from 10:30 am to 12:30 pm CDT
  • Location: Exhibit Hall, quadrant B, posterboard # B0428 (Session 423 – Neuro-Ophthalmology)

 

Contacts